A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy of AUY922, when administered weekly at 70 mg/m2, in adult
patients with advanced Non-small-cell Lung Cancer (NSCLC), who have received at least two
prior lines of chemotherapy. Patients will be retrospectively, and prospectively, stratified
based on their molecular tumor etiology. The following strata was assigned: Patients with
Epidermal growth factor receptor (EGFR) activating mutations, Patients with Kirstin Raus
sarcoma virus (KRAS) activating mutations, Patients with EML4-ALK (anaplastic lymphoma
kinase) translocations and patients that were both EGFR and Kras wild type.